| Title: |
Short-Term Effects of Dupilumab in Eosinophilic COPD |
| Authors: |
Lupia C.; Pastore D.; Marrazzo G.; Procopio G.; Giacalone A.; Marrelli F.; De Fina M.; De Francesco A. E.; Vatrella A.; Nolasco S.; Campisi R.; Crimi N.; Crimi C.; Pelaia G.; Pelaia C. |
| Contributors: |
Lupia, C.; Pastore, D.; Marrazzo, G.; Procopio, G.; Giacalone, A.; Marrelli, F.; De Fina, M.; De Francesco, A. E.; Vatrella, A.; Nolasco, S.; Campisi, R.; Crimi, N.; Crimi, C.; Pelaia, G.; Pelaia, C. |
| Publication Year: |
2026 |
| Subject Terms: |
chronic obstructive pulmonary disease; clinical practice; dupilumab; eosinophilic COPD; type 2 inflammation |
| Description: |
Background/Objectives: Patients with eosinophilic chronic obstructive pulmonary disease (COPD) often remain symptomatic despite optimized triple inhaled therapy. Dupilumab is a fully human monoclonal antibody that blocks the IL-4 receptor alpha subunit, thereby inhibiting IL-4 and IL-13 signaling. Evidence from randomized trials supports dupilumab for add-on treatment of type 2-high COPD, but data referring to short-term effectiveness in clinical practice are quite limited. Methods: We conducted an observational, compassionate-use study enrolling 13 consecutive outpatients with eosinophilic COPD (blood eosinophils ≥ 300 cells/μL) receiving add-on biologic therapy with dupilumab 300 mg every two weeks. Clinical (CAT, mMRC), functional (spirometry and body plethysmography), and inflammatory parameters (blood eosinophils/basophils, fibrinogen, FeNO) were evaluated at baseline and after four weeks of treatment. Safety was monitored after injection in a clinical setting, as well as via weekly phone follow-up. Results: Participants (84.6% male; mean age 67.08 ± 11.42 years) experienced rapid and clinically meaningful improvements at four weeks. CAT score decreased from baseline 21.40 ± 6.22 to 14.00 ± 5.58 (p < 0.001) and mMRC scale from 2.90 ± 0.73 to 1.80 ± 0.63 (p < 0.0001), respectively. Pre-bronchodilator FEV1 increased from baseline 1.35 ± 0.65 L to 1.59 ± 0.84 L (p < 0.05), and FVC from 2.36 ± 0.92 L to 2.83 ± 1.11 L (p < 0.01). A marked lung deflation was observed: indeed, residual volume declined from baseline 4.17 ± 1.98 L to 3.47 ± 2.07 L (p < 0.05), with a concomitant reduction in specific effective airway resistance (from baseline 3.15 ± 1.77 to 2.43 ± 1.44 kPa·s; p < 0.05) associated with significant increases in mid-expiratory flow (FEF25−75: from baseline 0.62 ± 0.38 to 0.86 ± 0.71 L/s; p < 0.05) and peak expiratory flow (3.80 ± 1.40 to 4.48 ± 1.79 L/s; p < 0.01). Type 2 inflammatory biomarkers changed as follows: blood eosinophil count fell from baseline 390.0 ± 43.75 to 190.0 ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41598712; info:eu-repo/semantics/altIdentifier/wos/WOS:001672186500001; volume:15; firstpage:1; lastpage:7; numberofpages:7; journal:JOURNAL OF CLINICAL MEDICINE; https://hdl.handle.net/11386/4936604 |
| DOI: |
10.3390/jcm15020775 |
| Availability: |
https://hdl.handle.net/11386/4936604; https://doi.org/10.3390/jcm15020775 |
| Accession Number: |
edsbas.A31DAF73 |
| Database: |
BASE |